Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of riociguat in symptomatic pulmonary arterial hypertension
2008-003610-94Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Primary endpoint: Long-term safety and tolerability. Started Oct 2008; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2008-003610-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003610-94.